split-banner-image

LBCT IV

Closed

LBCT IV

BCT Study Chair:

John Forbes

A trial to compare alternative adjuvant therapies combining endocrine and cytotoxic chemotherapy for patients with node positive operable breast cancer.

international

293

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

56

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

6

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

LBCT IV PUBLICATIONS

2016

Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies.

Bergh J, Pritchard KI, Cameron D. Journal of Clinical Oncology 2016; 34(9):895-897, Editorial

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.

Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thurlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A. Journal of Clinical Oncology. 2016; 34(9):927-935, Journal

2009

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.

Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Collins J, Fey MF, Coates AS, Goldhirsch A, International Breast Cancer Study Group (IBCSG). Breast Cancer Res Treat 2009; 117319-324, Journal

Second non-breast primary cancer following adjuvant therapy for early breast cancer: A report from the International Breast Cancer Study Group.

Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A. Eur J Cancer 2009; 45(4):561-571, Journal

2008

Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials.

Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A. J Clin Oncol 2008; 26(18):3006-3014, Journal

2007

Do patients with infiltrating lobular carcinoma (ILC) have an increased risk of contralateral, local, or distant recurrences compared with patients with infiltrating ductal carcinoma (IDC)?

Pestalozzi BC, Zahrieh D, Mallon E, Gusterson B, Gelber R, Price K, Castiglione-Gertsch M, Coates A, Goldhirsch A. SABCS 2007; Abstract 3078, Abstract

LOAD MORE

Institutions